Balaji Prasad
Stock Analyst at Barclays
(2.65)
# 2,275
Out of 4,829 analysts
147
Total ratings
83.33%
Success rate
9.98%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $9.98 | +150.63% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $7.59 | +44.93% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $25.02 | -4.08% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $8.95 | +0.56% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $103.59 | +93.07% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $12.82 | +48.21% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $44.19 | +35.78% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $161.68 | +50.92% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $8.71 | +175.70% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $24.41 | -9.87% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $509.43 | +2.07% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $17.92 | +45.13% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $106.69 | +49.97% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.92 | +22.13% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $10.19 | +76.64% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $2.89 | +246.02% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.01 | +593.07% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $9.98
Upside: +150.63%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $7.59
Upside: +44.93%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $25.02
Upside: -4.08%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $8.95
Upside: +0.56%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $103.59
Upside: +93.07%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $12.82
Upside: +48.21%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $44.19
Upside: +35.78%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $161.68
Upside: +50.92%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $8.71
Upside: +175.70%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $24.41
Upside: -9.87%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $509.43
Upside: +2.07%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $17.92
Upside: +45.13%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $106.69
Upside: +49.97%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.92
Upside: +22.13%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $10.19
Upside: +76.64%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $2.89
Upside: +246.02%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.01
Upside: +593.07%